Neuronetics investing in NeuroStar awareness as drug-free treatment alternative for depression

Neuronetics CEO Keith Sullivan joins Natalie Stoberman from the Proactive newsroom to discuss how its NeuroStar Advanced Therapy is emerging as an alternative for treating depression.

Sullivan explains that NeuroStar delivers a magnetic pulse to a specific part of the brain to reduce depression symptoms. With over 5 million successful treatments on nearly 150,000 patients, Sullivan says NeuroStar offers a promising alternative for those who have failed multiple drugs. However, he adds that there is a lack of awareness among patients and psychiatrists and the company intends to address this challenge by investing approximately $14 million in driving awareness within psychiatric practices and beyond.

Contact Details

Proactive Invesetors

+1 347-449-0879

na-editorial@proactiveinvestors.com